Market research
AGIO Agios Pharm
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 45.75
- Dividend yield
- Not available
- Beta
- 0.59
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US00847X1046
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 45.75
- Dividend yield
- Not available
- Beta
- 0.59
About
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AGIO discussion.
5 years, 4 months ago
Agios Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 17.5% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.6.
Agios Pharmaceuticals, Inc's total revenue rose by 24.3% to $44M since the same quarter in the previous year.
Its net income has increased by 4.6% to $-98M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.8% to $-50M since the same quarter in the previous year.
Based on the above factors, Agios Pharmaceuticals, Inc gets an overall score of 5/5.